[go: up one dir, main page]
Scribd Logo
Upload

Welcome to Scribd!

  • 547 views

    Pfizer

    Uploaded by

    Camille
    The document provides an internal factor evaluation (IFE) matrix and external factor evaluation (EFE) matrix for Pfizer. The IFE matrix lists strengths such as partnerships that increase revenues and weaknesses like declining sales in the US. The EFE matrix outlines opportunities such as growing overseas markets and threats like increased competition. Additional sections provide critical success factors, a competitive profile matrix comparing Pfizer to other companies, and templates for strategic alternatives.

    Copyright:

    © All Rights Reserved
    Download as XLSX, PDF, TXT or read online from Scribd

    Pfizer

    Uploaded by

    Camille
    547 views10 pages
    The document provides an internal factor evaluation (IFE) matrix and external factor evaluation (EFE) matrix for Pfizer. The IFE matrix lists strengths such as partnerships that increase revenues and weaknesses like declining sales in the US. The EFE matrix outlines opportunities such as growing overseas markets and threats like increased competition. Additional sections provide critical success factors, a competitive profile matrix comparing Pfizer to other companies, and templates for strategic alternatives.

    Original Description:

    Pfizer Strategic Management Matrices

    Copyright

    © © All Rights Reserved

    Available Formats

    XLSX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    The document provides an internal factor evaluation (IFE) matrix and external factor evaluation (EFE) matrix for Pfizer. The IFE matrix lists strengths such as partnerships that increase revenues and weaknesses like declining sales in the US. The EFE matrix outlines opportunities such as growing overseas markets and threats like increased competition. Additional sections provide critical success factors, a competitive profile matrix comparing Pfizer to other companies, and templates for strategic alternatives.

    Copyright:

    © All Rights Reserved
    Download as XLSX, PDF, TXT or read online from Scribd
    Download as xlsx, pdf, or txt
    547 views10 pages

    Pfizer

    Uploaded by

    Camille
    The document provides an internal factor evaluation (IFE) matrix and external factor evaluation (EFE) matrix for Pfizer. The IFE matrix lists strengths such as partnerships that increase revenues and weaknesses like declining sales in the US. The EFE matrix outlines opportunities such as growing overseas markets and threats like increased competition. Additional sections provide critical success factors, a competitive profile matrix comparing Pfizer to other companies, and templates for strategic alternatives.

    Copyright:

    © All Rights Reserved
    Download as XLSX, PDF, TXT or read online from Scribd
    Download as xlsx, pdf, or txt
    You are on page 1of 10

    Internal Factor Evaluation (IFE) Matrix

    Key Internal Factors


    Strengths
    1. Partnership venture with Ensai that allow Pfizer to generate a 20% increase in revenues from 2007 for Aricept
    2. Engages in the discovery, development, manufacture and marketing of prescription medicines for humans and an
    3. Double-digit international sales of the Pharmaceuticals business.
    4. Selling, General and Administrative Expenses declined from $15.59 billion in 2006 to $14.54 billion in 2008
    5. Largest company in the industry and is a gloal provider of innovative healthcare solutions
    6. Industry leader in terms of revenues, gross margins, operating margins and net income.
    7. Operates and innovates with partners, allies, mergers and acquisitions
    8. Good CSR efforts and activities that generated low-cost publicity, build consumer loyalty and keep inventory from
    9. Restructuring of Pfizer

    Weaknesses
    1. Double-digit decline of sales in the United States for the Pharmaceuticals segment
    2. R & D expenditures rose from $ 7.6 billion in 2006 to $ 7.9 billion in 2008
    3. Lowest earnings per share and price-earnings ratio among its direct competitors.
    4. Revenue decline from $48.42 billion in 2007 to $48.3 billion in 2008, decrease in net income from 2006-2008 by 2
    5. Pfizer spent nearly $5.6 million lobbying the US government
    6. Total liabilities increased from $43.48 billion in 2006 to $53.59 billion in 2008
    7. Decrease in liquidity ratios (Current ratio decreased by 13.96%, quick ratio decreased by 12.70%)
    8. Decrease in profitability ratios
    Total

    Weight

    Rating

    Weighted Score

    0.04
    0.06
    0.09
    0.05
    0.1
    0.06
    0.04
    0.04
    0.03

    3
    4
    4
    3
    4
    3
    4
    4
    3

    0.12
    0.24
    0.36
    0.15
    0.4
    0.18
    0.16
    0.16
    0.09

    0.09
    0.05
    0.05
    0.09
    0.06
    0.05
    0.05
    0.05
    1

    1
    2
    2
    1
    1
    2
    2
    2

    0.09
    0.1
    0.1
    0.09
    0.06
    0.1
    0.1
    0.1
    2.6

    3
    2
    4
    1
    3
    5
    5
    6

    4
    4
    2
    3
    4
    4
    4

    External Factor Evaluation (EFE) Matrix


    Key External Factors
    Opportunities
    1. Growing markets overseas
    2. Focus on low-income individuals in emerging markets
    3. Rising standards of living and increase in China's middle class
    4. Baby boomer population gets older and increasing life expectancies
    5. Recent scientific discoveries
    6. Diversification of product portfolio through partnership with Wyeth
    Threats
    1. Pfizer faces high competition due to the presence of many players in the industry.
    2. Law regulations in the United States and other regions around the world.
    3. Acquisitions could bring in more debt and litigations
    4. Troubled economy and increasing unemployment rate in the United States
    5. Patent expirations (Aricept)
    6. Unpredictable currency fluctuations
    Total

    atrix
    Weight

    Rating

    Weighted Score

    0.12
    0.1
    0.1
    0.1
    0.065
    0.08

    4
    4
    4
    3
    4
    4

    0.48
    0.4
    0.4
    0.3
    0.26
    0.32

    0.065
    0.08
    0.08
    0.06
    0.08
    0.07

    4
    2
    1
    4
    3
    1

    0.26
    0.16
    0.08
    0.24
    0.24
    0.07

    3.21

    1
    1.5
    1.5
    1.5
    3
    2

    3
    2
    2
    4
    2
    2.5

    0.0833333333

    Critical Success Factors


    1. Product innovation (R&D)
    2. Market Share
    3. Organization size (economies of scale)
    4. Product Quality
    5. Financial position
    6. Marketing & Advertising
    7. HR and Management
    8. Global Expansion
    9. Product Portfolio
    Total

    Competitive Profile Matrix


    Merck
    Weight
    Rating
    Score
    0
    2
    2
    2

    Matrix
    Novartis
    Rating
    Score

    Pfizer

    Rating

    Score

    3
    3

    Financial Position

    Total

    Ratings

    0
    Industry Position

    Total

    0
    Stability Position

    Total

    0
    Competitive Position

    Total

    SP Average

    CP Average

    IP Average

    FP Average

    x-axis

    y-axis

    Key Factors
    Opportunities

    Threats

    Strengths

    Weaknesses

    Total

    STRATEGIC ALTERNATIVES
    Weight

    AS

    TAS

    AS

    TAS

    You might also like